A Study of Olverembatinib in the Treatment of Myeloid/Lymphoid Tumors With FGFR1 Rearrangement

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

FGFR1-rearranged myeloid/lymphoid neoplasms are a rare hematologic malignancy with very poor outcome despite intensive chemotherapy. The only curative option is thought to be allogeneic hematopoietic stem cell transplantation (HSCT) in remission. This phase II study is aimed to evaluate the efficacy of Olverembatinib, consolidated with HSCT in the treatment of FGFR1-rearranged myeloid/lymphoid neoplasm.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• Patients with newly diagnosed, progressed or relapsed myeloid/lymphoid neoplasms with FGFR1 rearrangement according to the WHO-2016 diagnostic criteria. Patients who have received allogeneic hematopoietic stem cell transplantation or ponatinib should be excluded.

• ECOG score: MPNs patients, 0-3 points; AL patients, 0-2 points.

• Expected survival period ≥12 weeks.

• Willingness and ability to comply with study procedures and follow-up examination.

Locations
Other Locations
China
First Affiliated Hospital of Soochow University
RECRUITING
Suzhou
Contact Information
Primary
Suning Chen
chensuning@sina.com
+86-13814881746
Time Frame
Start Date: 2022-09-01
Estimated Completion Date: 2027-08-31
Participants
Target number of participants: 20
Treatments
Experimental: Treatment Group
Related Therapeutic Areas
Leukemia
Sponsors
Leads: The First Affiliated Hospital of Soochow University

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

A Pilot/Phase 1 Study of Immunosuppression-free Regulatory T-cell Graft-engineered Haploidentical Hematopoietic Cell Transplantation in Relapsed/Refractory and Ultra-High-risk AML/MDS

A Pilot/Phase 1 Study of Immunosuppression-free Regulatory T-cell Graft-engineered Haploidentical Hematopoietic Cell Transplantation in Relapsed/Refractory and Ultra-High-risk AML/MDS

Who is this study for: Patients with relapsed/refractory acute myeloid leukemia and/or myelodysplastic syndromes
Enrollment Status: Recruiting
Publish Date: October 20, 2025
Intervention Type: Drug, Biological, Radiation, Procedure
Study Drugs: Fludarabine, Thiotepa, Cyclophosphamide, Mesna, Treg-enriched donor cell, Unmodified donor T Cell
Study Phase: Phase 1

A Phase 1 Dose-escalation Study Testing the Feasibility and the Tolerance of Infusion of a Specific Third Party Suicide Gene-transduced Anti-HLA-DPB1*0401 CD4+ T Cell Clone in HLA-DPB1*04:01 Positive Tumor Recipients Receiving an Allotransplant From a HLA-DPB1*04:01 Negative Donor.

A Phase 1 Dose-escalation Study Testing the Feasibility and the Tolerance of Infusion of a Specific Third Party Suicide Gene-transduced Anti-HLA-DPB1*0401 CD4+ T Cell Clone in HLA-DPB1*04:01 Positive Tumor Recipients Receiving an Allotransplant From a HLA-DPB1*04:01 Negative Donor.

Who is this study for: Patients HLA-DPB1*04:01 positive, with hematologic malignancies undergoing an allo-HSCT using a HLA-DPB1*04:01 negative donor
Enrollment Status: Recruiting
Publish Date: January 26, 2026
Intervention Type: Combination product
Study Drug: CTL 19
Study Phase: Phase 1

Chidamide Prevents the Recurrence of High-risk Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem-cell Transplantation: A Prospective, Single-centered, Single-arm, Phase I/II Clinical Study

Chidamide Prevents the Recurrence of High-risk Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem-cell Transplantation: A Prospective, Single-centered, Single-arm, Phase I/II Clinical Study

Enrollment Status: Recruiting
Publish Date: January 12, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View All